Abstract 627P
Background
The prevalence of multiple primary neoplasms has been increasing over time, with primary colorectal cancer and primary prostate cancer being a common coexistence. Notably, a primary prostatic cancer was discovered in approximately one-sixth of men who underwent prostate cancer screening prior to rectal cancer excision. Due to a lack of knowledge about the racial disparity factor in this multiple primary malignancy, our study aims to assess the risk of developing primary prostate cancer between African Americans and Caucasians in patients with colorectal cancer.
Methods
We extracted the data from cancer registries in the Surveillance, Epidemiology, and End Results (SEER) database for patients with primary colorectal cancer from 2000-2020. This allowed us to compare the risk of developing primary prostate cancer between African American and Caucasian individuals. We used MP-SIR session to estimate the SIR (standardized incidence ratios) as observed/expected (O/E), and excess absolute risk (EAR) per 10,000 patients using 95% Confidence intervals (CI), with significant result when p <0.05. The latency exclusion period was set at 0 month.
Results
Among 721,385 patients included in the study with primary colorectal cancer, only 8,943 (1.24%) developed primary prostate cancer (Expected= 8,938.87, O/E= 1.00, p >0.05, 95% CI: 0.98-1.02, EAR= 0.01). Out of these cases, approximately 7,340 (82.1%) were Caucasian individuals who developed primary prostate cancer (Expected= 7,633.79, O/E= 0.96, p <0.05, 95% CI: 0.94-0.98, EAR= -1.03), while only 1,603 (17.9%) were African American individuals who developed primary prostate cancer (Expected= 1,305.08, O/E= 1.23, P <0.05, 95% CI: 1.17-1.29, EAR= 7.82). Notably, at the age of 70-74 years, Caucasian individuals exhibited a significant decrease in the risk of developing primary prostate cancer (O/E= 0.91, P <0.05, EAR= -4.12), whereas African American individuals showed a significant increase in risk at this age (O/E= 1.27, P <0.05, EAR= 14.32).
Conclusions
Our results show a higher risk of developing primary prostate cancer in African American patients compared to Caucasian patients. Further research is needed to better understand the race variations on a genetic basis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract